Immunogenicity and safety of Vi capsular polyssacharide typhoid vaccine in healthy persons in Korea

Sang Min Lim, Hahn Sun Jung, Ja Kim Min, Dae Won Park, Woo Joo Kim, Hee-Jin Cheong, Seung Chul Park, Kwang Chul Lee, Young Kyoo Shin, Hyun Kwang Tan, Sang Lin Kim, Jang Wook Sohn

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the immunogenicity and safety of Salmonella Typhi Vi capsular polysaccharide vaccine (Vi vaccine) in Korea. The immunogenicity of a single dose of Vi vaccine was evaluated in 157 subjects (75 children and 82 adults) before and at 1, 6, and 12 months after vaccination. Immunogenicity was measured with a passive hemagglutination assay (PHA), quantified as geometric mean titers (GMTs) and seroconversion rates. The safety of the vaccine was investigated by determining adverse reactions occurring within 4 h, 3 days, and 1 month after injection. The seroconversion rate for children and adults 1 month after vaccination was 96.92% and 89.02%, respectively. In the case of children, the GMTs of Vi antibodies before vaccination were 5.8±1.34 and 142.59±2.39 at one month after vaccination. For adults, the GMTs before and one month after vaccination were 5.58±1.28 and 58.56±3.67, respectively. Vi antibodies persisted for as long as 6 and 12 months after vaccination. All adverse reactions in adults and children were minor and did not require treatment. The Vi CPS vaccine was safe and immunogenic in adults and children older than 5 years.

Original languageEnglish
Pages (from-to)611-615
Number of pages5
JournalJournal of Microbiology and Biotechnology
Volume17
Issue number4
Publication statusPublished - 2007 Apr 1

    Fingerprint

Keywords

  • Immunogenicity
  • Safety
  • Vi capsular polysaccharide typhoid vaccine

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Microbiology
  • Bioengineering

Cite this